analyzeportfolio
NYSE · Real Estate

Medical Properties Trust Inc. (MPT)

As-reported financials and SEC filings for Medical Properties Trust Inc. The latest annual period is FY2025. The latest reported quarter is Q1 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About Medical Properties Trust Inc.

Medical Properties Trust Inc is a real estate investment trust that acquires and develops healthcare facilities, which it leases to healthcare operators under long-term net leases. Its portfolio includes general acute care hospitals, behavioral health facilities, post-acute care facilities, and freestanding emergency or urgent care centers across the United States, Europe, and South America. The company also provides mortgage loans to healthcare operators and occasionally makes noncontrolling investments in its tenants.

Snapshot

Revenue
$972.0M
Revenue growth (YoY)
-2.4%
Net income
$-277.0M
Diluted EPS
$-0.46
Gross margin
90.7%
Operating margin
—
Net margin
-28.5%
FCF margin
—
ROE
-6.0%
net income / fiscal-year-end equity
P/E
n/m
not meaningful: a reported loss in the fiscal year or the trailing twelve months
Market cap
$1.88B
Long-term debt / equity
2.10×
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Medical Properties Trust

  • Revenue fell 2.4% to $972M in FY2025, slower than the 14.2% the year before.
  • Most recent quarter Q1 FY2026: revenue $252M, up 12.6% from Q1 FY2025.
  • Net loss narrowed to $277M in FY2025, from $2.4B in FY2024.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Medical Properties Trust’s fundamentals sit among the 165 REITs. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin90.7%
Highest of 27
Net margin-28.5%
10th percentile of 157
Revenue growth (YoY)-2.4%
27th percentile of 161
ROE-6.0%
16th percentile of 142
Long-term debt / equity2.10×
79th percentile of 100
Short interest11.81d
99th percentile of 154

Medical Properties Trust’s gross margin of 90.7% is the highest of the 27 REITs reporting it. Medical Properties Trust’s net margin of -28.5% ranks in the 10th percentile of the 157 REITs reporting it.

1 reported insider purchase (code P) totaling $9,545 in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 2 of the superinvestors we track (plus 5 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
2
+5 quant / multi-strat
Initiated / added
3
0 new, 3 added
Reduced / exited
3
3 trimmed, 0 exited
Combined position
$144.5M
reported long value
InvestorAs ofPosition valueSharesChange
AQR Capital ManagementquantQ2 2026$81.1M17.6MAdded
Two Sigma InvestmentsquantQ2 2026$33.7M7.3MReduced
Coatue ManagementQ2 2026$20.9M4.5MHeld
Citadel AdvisorsquantQ2 2026$5.8M1.3MAdded
Millennium ManagementquantQ2 2026$2.4M529.3KAdded
Bridgewater AssociatesQ2 2026$411,78589.1KReduced
D. E. ShawquantQ2 2026$128,05727.7KReduced

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
1
1 insider
Bought (90d)
$10K
code P value
Sells (90d)
0
—
Reported activity
Net buying
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-20
James Kevin HannaSenior VP, Controller & CAOBuy2.3K$4.15$10K

Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
146.2M
settled 2026-09-30
Change vs prior
+0.6%
vs previous settlement
Days to cover
11.81
at avg daily volume
Avg daily volume
12.4M
FINRA reported
SettlementShares shortChangeDays to cover
2026-09-30146.2M+0.6%11.81
2026-09-15145.3M-3.2%15.13
2026-08-31150.1M+3.9%20.89
2026-08-14144.5M+0.2%15.55
2026-07-31144.3M+4.4%30.82
2026-07-15138.2M+0.1%22.89
2026-06-30138.1M+5.0%16.93
2026-06-15131.6M-1.2%24.17

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$972.0M$995.5M$871.8M$1.54B$1.54B
Gross profit——
Operating income—————
Net income$-277.0M$-2.41B$-556.5M$902.6M$656.0M
Diluted EPS$-0.46$-4.02$-0.93$1.50$1.11

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2025FY2024FY2023FY2022FY2021
Cash and equivalents$540.9M$332.3M$250.0M$235.7M$459.2M
Current assets—————
Total assets$15.00B$14.29B$18.30B$19.66B$20.52B
Current liabilities—————
Long-term debt$9.70B$8.85B$10.06B$10.27B$11.28B
Total liabilities$10.39B$9.46B$10.67B$11.06B$12.07B
Total equity$4.61B$4.83B$7.63B$8.59B$8.45B

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$230.8M$245.5M$505.8M$739.0M$811.7M
Capital expenditure—————
Free cash flow—————

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Quarterly trend

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q1 FY2026$252.1M12.6%$32.8M$0.05
Q4 FY202516.6%
Q3 FY2025$237.5M5.2%$-77.7M$-0.13
Q2 FY2025$240.4M-9.8%$-98.4M$-0.16
Q1 FY2025$223.8M-17.5%$-118.3M$-0.20
Q4 FY2024—
Q3 FY2024$225.8M-26.3%$-801.2M$-1.34
Q2 FY2024$266.6M-21.0%$-320.6M$-0.54

Latest 8 quarters, from company XBRL filings on SEC EDGAR. A dotted underline marks a fourth-quarter figure we calculated from the full year and the first nine months. Revenue YoY is our calculation too: each quarter against the same quarter a year earlier.

Company facts

ExchangeNYSE
SectorReal Estate
SIC industryReal Estate Investment Trusts
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ1 FY2026 (ended March 31, 2026)
Oldest indexed filing2010
SEC CIK1287865

Selected SEC filings

10-K2026-02-26
View on EDGAR →
10-Q2026-08-10
View on EDGAR →
10-Q2026-05-08
View on EDGAR →
8-K2026-08-10
View on EDGAR →
8-K2026-08-10
View on EDGAR →
8-K2026-06-01
View on EDGAR →
8-K2026-04-30
View on EDGAR →

Largest reit peers

All reit stocks →All Real Estate companies →

Monitor MPT

Get an alert when Medical Properties Trust files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor MPT free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.